Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Secondary Malignant Neoplasm

Cancer Family

Secondary Malignant Neoplasm

CI-CAN-00000346SMNExplore in graph →

4,270 active trials56 approved drugs532 evidence items

NCIt: C4968

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14664
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
· J Clin Oncol · 2009 · PMID 19289619 · validated civic_curation pubmed
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
· Lancet Oncol · 2014 · PMID 24793816 · validated civic_curation pubmed
Trastuzumab emtansine for HER2-positive advanced breast cancer.
· N Engl J Med · 2012 · PMID 23020162 · validated civic_curation pubmed
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
· J Clin Oncol · 2016 · PMID 27091708 · validated civic_curation pubmed
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
· N Engl J Med · 2012 · PMID 22149875 · validated civic_curation pubmed
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
· Lancet · 2012 · PMID 22257673 · validated civic_curation pubmed
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
· Cancer Res · 2013 · PMID 23204226

Showing 51–75 of 486 publications

← Previous
1
2
3
4
…
20
Next →

· validated civic_curation

Integrative clinical genomics of advanced prostate cancer.

· Cell · 2015 · PMID 26000489 · validated cbioportal_study pubmed

The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.

· Oncotarget · 2016 · PMID 27172793 · validated civic_curation pubmed

Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma.

· PLoS One · 2015 · PMID 26207647 · validated civic_curation pubmed

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.

· Cancer · 2013 · PMID 22810899 · validated civic_curation pubmed

MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.

· Sci Rep · 2016 · PMID 27819322 · validated civic_curation pubmed

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

· J Clin Oncol · 2011 · PMID 21172893 · validated civic_curation pubmed

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18682506 · validated civic_curation pubmed

The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma.

· Clin Cancer Res · 2006 · PMID 16467086 · validated civic_curation pubmed

When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?

· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.

· Clin Cancer Res · 2017 · PMID 28476872 · validated civic_curation pubmed

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

· Lancet Oncol · 2012 · PMID 22285168 · validated civic_curation pubmed

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

· Oncotarget · 2017 · PMID 28103578 · validated civic_curation pubmed

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28526536 · validated civic_curation pubmed

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

· J Clin Oncol · 2016 · PMID 26951309 · validated civic_curation pubmed

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

· Eur Urol · 2017 · PMID 27751729 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

· Cancer Discov · 2018 · PMID 29773717 · validated civic_curation pubmed

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

· Cancer Discov · 2019 · PMID 31575541 · validated civic_curation pubmed